Lifecore Biomedical Files 8-K for Financials
Ticker: LFCR · Form: 8-K · Filed: Jan 17, 2025 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
TL;DR
Lifecore Biomedical filed an 8-K for financial statements and exhibits. Keep an eye on disclosures.
AI Summary
On January 17, 2025, Lifecore Biomedical, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific transactions or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Lifecore Biomedical, Inc. is providing updated financial information or exhibits to the SEC, which could be relevant for investors assessing the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate adverse events.
Key Numbers
- 000-27446 — SEC File Number (Identifies the company's filing with the SEC.)
- 94-3025618 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Lifecore Biomedical, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Chaska, Minnesota (location) — Principal executive offices
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided excerpt states that the filing includes 'Financial Statements and Exhibits' but does not specify the exact nature or content of these documents.
Does this 8-K report any new material events or changes in the company's business?
The excerpt lists 'Other Events' and 'Financial Statements and Exhibits' as item information, but does not detail any specific new material events beyond the filing of financial documents.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 17, 2025.
What is Lifecore Biomedical, Inc.'s principal executive office address?
Lifecore Biomedical, Inc.'s principal executive offices are located at 3515 Lyman Boulevard, Chaska, Minnesota 55318.
Has Lifecore Biomedical, Inc. changed its name or former address recently?
The filing indicates 'Not Applicable' for former name or former address, if changed since last report, suggesting no recent changes.
Filing Stats: 1,139 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2025-01-17 17:27:19
Key Financial Figures
- $0.001 — f shares of its common stock, par value $0.001 per share ("Common Stock") issuable upo
Filing Documents
- lndc-20250117.htm (8-K) — 30KB
- a2025-01x17form8xkex991.htm (EX-99.1) — 15KB
- image_0a.jpg (GRAPHIC) — 50KB
- 0001005286-25-000028.txt ( ) — 242KB
- lndc-20250117.xsd (EX-101.SCH) — 2KB
- lndc-20250117_lab.xml (EX-101.LAB) — 21KB
- lndc-20250117_pre.xml (EX-101.PRE) — 12KB
- lndc-20250117_htm.xml (XML) — 3KB
01 Other Event
Item 8.01 Other Event. On January 17, 2025, Lifecore Biomedical, Inc. ("Lifecore" or the "Company") issued a press release announcing that it intends to hold a special meeting of its stockholders (the "Special Meeting") on April 10, 2025 to consider and vote on a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of its common stock, par value $0.001 per share ("Common Stock") issuable upon conversion of shares of the Company's Series A Convertible Preferred Stock, par value $0.001 per share (the "Convertible Preferred Stock") in an amount in excess of 19.99% of the number of shares of the Common Stock outstanding immediately prior to the issuance of such Convertible Preferred Stock (the "Proposal"). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or the Company's future performance that involve certain contingencies and uncertainties. The forward-looking statements include, without limitation, the Company's plans and expectations regarding the proposed Special Meeting and the Proposal, and the Company's intention with respect to future capital raising activities. These forward-looking statements are not guarantees of future performance, and all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such a difference include, without limitation, the ability for the Company to hold the Special Meeting on the anticipated timeline, if at all, changes in the Company's liquidity needs, as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission, including the C
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished as part of this report: Exhibit No. Description 99.1 Press Release issued January 17, 2025 by Lifecore Biomedical, Inc. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 17, 2025 LIFECORE BIOMEDICAL, INC. By: /s/ Ryan D. Lake Ryan D. Lake Chief Financial Officer